El Paso Regenerative Therapies for Better Gut Health

El Paso Regenerative Therapies for Better Gut Health: BPC-157, Leaky Gut, and Integrative Care

Abstract

Gut health depends on much more than digestion. The intestinal lining acts as a protective barrier, absorbs nutrients, communicates with the immune system, and interacts with trillions of microorganisms that make up the gut microbiome. When that lining is damaged, intestinal permeability may increase, inflammation may rise, and normal repair processes may become less effective.

Regenerative medicine is being studied to support intestinal tissue repair, immune balance, and the gut microbiome. Research involving intestinal stem cells, cell-based therapies, microbiome treatments, and signaling molecules shows exciting potential. BPC-157, a 15-amino-acid experimental peptide, has also attracted attention because laboratory and animal studies suggest it may support blood-vessel formation, tissue repair, and protection of the gastrointestinal lining. However, human evidence remains very limited, and BPC-157 is not an FDA-approved treatment.

An integrative approach can bring these different areas together. At Injury Medical Clinic PA in El Paso, Texas, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, works within a multidisciplinary model that combines chiropractic care, functional medicine, rehabilitation, personal injury care, and medical collaboration. Dr. Maria Guadalupe Cardenas, MD, a board-certified internal medicine physician with more than 40 years of experience, serves as the clinic’s medical director and collaborative physician. This model considers digestive health, inflammation, movement, nutrition, injury recovery, and general medical risks together.

Can Regenerative Therapies Help With Gut Health?

The short answer is possibly, but the strength of the evidence depends on the therapy.

The intestine already has a remarkable ability to regenerate. Cells covering the intestinal wall are replaced rapidly. Special intestinal stem cells help produce new epithelial cells that maintain the barrier between the contents of the digestive tract and the rest of the body.

Researchers are now studying ways to improve this natural repair system when it becomes damaged by inflammation, aging, radiation, immune disease, or other health problems.

A 2025 review of cell-based therapies for digestive disorders found that stem-cell-related approaches may eventually help regenerate damaged tissues, influence immune activity, and support healing in conditions such as Crohn’s disease. However, researchers also emphasized major challenges involving safety, manufacturing, immune reactions, and translation from experimental research into routine medical care (Liang et al., 2025).

This means regenerative medicine for the digestive system is promising, but much of it remains an emerging area of medicine rather than standard treatment.

The Gut Lining Is a Living Protective Barrier

Think of the intestinal lining like a security wall.

It must allow nutrients, water, vitamins, and minerals to pass through while helping keep unwanted bacteria, toxins, and inflammatory substances from crossing into the bloodstream.

When this barrier is injured, intestinal permeability may increase. This is commonly described as “leaky gut.” Increased intestinal permeability is recognized in several gastrointestinal and inflammatory diseases, although “leaky gut syndrome” should not automatically be treated as a separate diagnosis without proper medical evaluation.

The microbiome is also important. Gut bacteria communicate with intestinal cells and the immune system.

Research suggests that changes in the microbiome can influence:

• Intestinal barrier strength
• Immune signaling
• Inflammatory activity
• Nutrient metabolism
• Intestinal stem-cell behavior
• Tissue repair

Williams et al. (2023) described the gut microbiome as a possible target within regenerative medicine because changing the intestinal microbial environment may influence inflammation and the body’s own repair systems.

The Microbiome May Help Control Intestinal Regeneration

New research has strengthened the connection between gut bacteria and intestinal stem cells.

Nalapareddy et al. (2026) studied aging intestinal stem cells in mice. The researchers found that age-related changes in gut bacteria affected signaling pathways involved in intestinal stem-cell activity. Transferring microbiota from younger mice improved regenerative responses in older mice.

This does not mean that transferring a young person’s microbiome is currently an anti-aging gut treatment. The study was mainly experimental. However, it provides important evidence that the microbiome can directly influence intestinal regeneration.

Researchers are finding similar connections in other areas. A 2025 study described by the Leibniz Institute for Immunotherapy found that a bacterial metabolite called desaminotyrosine supported intestinal stem-cell repair in experimental models after cancer treatment and stem-cell transplantation. Higher levels of the metabolite were also associated with better outcomes in patients receiving stem-cell transplants, although more research is required before it can become a routine therapy.

These findings support an important idea:

Healthy gut bacteria may help create an environment in which intestinal repair systems can work properly.

Regenerative Cell Therapy and the Intestinal Barrier

Stem-cell research is another important part of regenerative gut medicine.

Scientists are investigating whether intestinal stem cells, engineered intestinal tissue, organoids, and other cell-based therapies could eventually help repair damaged intestinal tissue.

The California Institute for Regenerative Medicine has supported research examining intestinal organoids and intestinal progenitor cells for inflammatory bowel disease. One goal is to restore the epithelial barrier by supporting both transplanted cells and the patient’s existing intestinal stem cells.

Another experimental approach involves removing aging or “senescent” cells.

Eskiocak et al. (2026) reported that an experimental CAR T-cell treatment targeting senescent cells improved intestinal barrier function, regeneration, inflammation, and microbiome composition in aged mice. The results offer proof of concept rather than a treatment currently available for routine gut-health care.

Research involving mesenchymal stem cells has also created interest in problems such as inflammatory digestive disorders and gastroparesis. However, commercial discussions about stem-cell therapy should not be confused with established clinical evidence. Some organizations offering these treatments specifically acknowledge that the FDA has not approved such advanced cell therapies for these digestive indications in the United States.

Where Does BPC-157 Fit Into Gut Regeneration?

BPC-157 stands for Body Protection Compound-157. It is a synthetic peptide made from 15 amino acids and was developed from research involving compounds associated with gastric proteins.

BPC-157 has received attention because animal and laboratory studies suggest several possible actions relevant to intestinal repair.

Researchers have reported possible effects involving:

• Protection of gastrointestinal tissues
• Formation of new blood vessels
• Fibroblast activity
• Collagen production
• Nitric oxide signaling
• Inflammatory pathways
• Tissue repair
• Microvascular circulation

A 2026 review by Yuan et al. found that BPC-157 showed gastrointestinal and tissue-repair effects across several preclinical models. However, the authors stressed that human research remains extremely limited (Yuan et al., 2026).

This distinction is critical.

BPC-157 has promising research—but mostly in animals.

What happens in a rat, mouse, rabbit, or laboratory cell does not automatically happen the same way in a human patient.

Could BPC-157 Help With “Leaky Gut”?

This is one reason BPC-157 has become popular online.

Preclinical studies suggest that it may support epithelial healing and cytoprotection. In theory, protecting epithelial cells and encouraging tissue repair could help maintain the intestinal barrier after injury.

Researchers have also studied BPC-157 in experimental models involving stomach injuries, ulcers, intestinal inflammation, and other gastrointestinal damage.

However, there is currently not enough high-quality human evidence to say that BPC-157 safely treats increased intestinal permeability or “leaky gut.”

A detailed 2026 review found that BPC-157 has:

• No approved pharmaceutical formulation
• No validated human dosing schedule
• Very limited human pharmacokinetic information
• Fewer than 30 participants across the small human studies reviewed
• No completed Phase II clinical trial establishing effectiveness

(Mateescu et al., 2026).

Therefore, BPC-157 should be described as an investigational peptide, not a proven gut-healing medication.

An Important FDA Update on BPC-157

The regulatory situation is especially important for patients considering peptide therapy.

In July 2026, the FDA reviewed BPC-157 free base and BPC-157 acetate for possible use in pharmacy compounding. The agency found insufficient evidence supporting the effectiveness of BPC-157 for ulcerative colitis and insufficient clinical information to clearly establish its safety. The FDA proposed excluding both forms from the 503A Bulks List.

FDA materials also noted that no human studies used the proposed oral, subcutaneous, nasal, or transdermal routes for ulcerative colitis and raised concerns about immunogenicity and peptide-related impurities.

For this reason, patients should be cautious about websites that describe BPC-157 as an established medication for Crohn’s disease, ulcerative colitis, IBS, or leaky gut.

BPC-157 is not an FDA-approved drug for these conditions.

Integrative Peptide Therapy Should Look Beyond One Peptide

The broader concept of integrative peptide therapy is not simply about giving someone a peptide.

A responsible clinical approach begins by asking why the digestive system is struggling.

Possible contributing factors may include:

• Poor diet
• Chronic gastrointestinal disease
• Food intolerance
• Medication effects
• Excess alcohol use
• Infection
• Altered gut bacteria
• Poor sleep
• Metabolic disease
• Chronic stress
• Autoimmune disease
• Nutrient deficiencies

Treating a peptide as a shortcut while ignoring these problems may miss the real cause.

Nutrition, adequate protein, appropriate fiber, hydration, physical activity, sleep, and management of diagnosed gastrointestinal disease are all important for maintaining the intestinal barrier and microbiome.

How Integrative Chiropractic Care Fits Into Gut Health

Chiropractic care should not be presented as a direct treatment that “seals” a leaky intestinal lining.

Its role in an integrative model is different.

Dr. Alexander Jimenez’s published clinical observations emphasize considering both the biological and mechanical environments of recovery. His clinical materials describe evaluating factors such as inflammation, nutrition, sleep, stress, digestive health, mobility, strength, and physical function rather than focusing only on one painful structure.

For a person recovering from an injury while also experiencing digestive problems, an integrative chiropractic and rehabilitation program may help address:

• Spinal and joint mobility
• Muscle tension and guarding
• Posture
• Physical activity tolerance
• Corrective exercise
• Strength
• Movement mechanics
• Return to normal activities

Meanwhile, gastrointestinal disease, abnormal laboratory results, medication issues, severe abdominal symptoms, or possible inflammatory disease require appropriate medical evaluation.

This separation of roles is important. Chiropractic care can support the musculoskeletal side of recovery, while medical and nutritional care address gastrointestinal disease and systemic health.

Dr. Jimenez and Dr. Cardenas: A Multidisciplinary Model in El Paso

At Injury Medical Clinic PA in El Paso, Texas, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, works within a multidisciplinary clinical model.

Practice materials describe the clinic as integrating:

• Chiropractic care
• Functional medicine
• Medical evaluation and oversight
• Personal injury treatment
• Rehabilitation
• Nutrition and lifestyle strategies
• Musculoskeletal medicine
• Coordinated clinical services

The practice identifies Dr. Maria Guadalupe Cardenas, MD, as a board-certified internal medicine physician, medical director, and collaborative physician. She has more than 40 years of internal medicine experience. The practice lists Texas medical license J2933 and lists her NPI as #1164426749.

Dr. Cardenas can bring an internal medicine viewpoint to medical screening, chronic disease, medication safety, laboratory findings, and conditions that require medical treatment. Dr. Jimenez focuses on chiropractic, nurse-practitioner-led care, functional medicine, injury management, rehabilitation, and physical function.

This type of collaboration can be valuable because gut symptoms do not always come from one cause. Abdominal pain, unexplained weight loss, blood in the stool, persistent vomiting, anemia, fever, severe diarrhea, or ongoing digestive symptoms should be medically evaluated rather than assumed to be “leaky gut.”

The Future of Regenerative Gut Health

Regenerative medicine is helping researchers understand that the intestinal lining is not a passive tube. It is a living, rapidly renewing system controlled by stem cells, immune signals, blood flow, nutrition, and the microbiome.

The future may include therapies that:

• Activate intestinal stem cells
• Restore damaged epithelial barriers
• Modify harmful inflammatory signaling
• Use microbial metabolites to encourage repair
• Rebalance selected components of the microbiome
• Develop engineered intestinal tissues or organoids
• Target aging cells that interfere with regeneration

BPC-157 remains an interesting part of this research story, particularly because of its reported gastrointestinal effects in preclinical studies. But interest should not be confused with proof.

For now, the best approach is to combine emerging science with careful diagnosis, evidence-based treatment, healthy nutrition, rehabilitation, appropriate medical oversight, and realistic expectations.

That is where multidisciplinary care becomes especially useful: supporting the body’s healing environment while making sure serious disease is identified and treated appropriately.

References

Eskiocak, O., Gewolb, J., Shah, V., et al. (2026). Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness. Nature Aging, 6, 108–126.

Jimenez, A. (2026). Regenerative medicine and integrative chiropractic approaches. Injury Medical Clinic PA.

Jimenez, A. (2026). Regenerative therapies for fitness and recovery insights. Injury Medical Clinic PA.

Liang, G., Ma, Y., Deng, P., & Li, S. (2025). Role of cell-based therapies in digestive disorders: Obstacles and opportunities. Regenerative Therapy, 29, 1–18.

Mateescu, D.-M., Gavrilescu, D.-M., Constantinescu, F. E., et al. (2026). BPC-157 as an investigational peptide therapeutic: Biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics, 18(5), 625.

Nalapareddy, K., Haslam, D. B., Kissmann, A.-K., et al. (2026). Microbiota from young mice restore the function of aged ISCs. Stem Cell Reports, 21(2), 102788.

U.S. Food and Drug Administration. (2026). July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials.

Williams, K. L., Enslow, R., Suresh, S., Beaton, C., Hodge, M., & Brooks, A. E. (2023). Using the microbiome as a regenerative medicine strategy for autoimmune diseases. Biomedicines, 11(6), 1582.

Yuan, C., Demers, A., Silva-Ortiz, V., Hasoon, J. J., Lee, W., Dave, K., Amirdelfan, K., Burke, H. W., Christo, P. J., & Robinson, C. L. (2026). From regeneration to analgesia: The role of BPC-157 in tissue repair and pain management. International Journal of Molecular Sciences, 27(6), 2876.

International Society for Stem Cell Research. (2026). New study shows gut microbiota directly regulates intestinal stem cell aging.

Leibniz Institute for Immunotherapy. (2025). Protecting the gut after stem cell transplantation: New evidence for the potential of microbiome-based therapies.

California Institute for Regenerative Medicine. (n.d.). Stem cell therapy for inflammatory bowel disease.